Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 14/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737575 | 0.89 | ABCB1 (0.52) | ABCB1MAOBMAOA | |
| SCHEMBL6740461 | 0.86 | ABCB1 (0.53) | ABCB1MAOBMAOA | |
| SCHEMBL6742472 | 0.85 | ABCB1 (0.58) | ABCB1MAOBMAOA | |
| SCHEMBL6737479 | 0.84 | ABCB1 (0.60) | ABCB1MAOBMAOA | |
| SCHEMBL6742959 | 0.83 | ABCB1 (0.61) | ABCB1MAOBMAOA | |
| SCHEMBL6739520 | 0.83 | ABCB1 (0.56) | ABCB1MAOBMAOA | |
| SCHEMBL6744428 | 0.81 | ABCB1 (0.57) | ABCB1MAOBMAOA | |
| SCHEMBL6744484 | 0.81 | ABCB1 (0.54) | ABCB1MAOBMAOA | |
| SCHEMBL6737859 | 0.81 | ABCB1 (0.56) | ABCB1MAOBMAOA | |
| SCHEMBL6741749 | 0.81 | ABCB1 (0.54) | ABCB1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689808-B2 | TREATING OR PREVENTING EPILEPSY OR NEURODEGENERATIVE DISEASES | LES LABORATOIRES SERVIER (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20030220393-A1 | Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220393-A1 | Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them | NR5A2, NR2E3, NR4A1 | ABCB1 1291/4885MAOB 1112/4885TAS1R3 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.